The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Early Detection and Accurate Description of Extent of Metastatic Bone Disease in Breast Cancer With Fluoride Ion and Positron Emission Tomography
Abstract
PURPOSE: Previous studies have shown that bone metastases are revealed by magnetic resonance imaging (MRI) or bone marrow scintigraphy several months before they are visible by conventional bone scintigraphy (BS). We present a new approach for detecting bone metastases in patients with breast cancer. We compared findings obtained with fluoride ion (F-18) and positron emission tomography (PET) with those obtained with conventional BS. PATIENTS AND METHODS: Thirty-four breast cancer patients were prospectively examined using F-18–PET and conventional BS. F-18–PET and BS were performed within 3 weeks of each other. Metastatic bone disease was previously known to be present in six patients and was suspected (bone pain or increasing levels of tumor markers, Ca 2+, alkaline phosphatase) in 28 patients. Both imaging modalities were compared by patient-by-patient analysis and lesion-by-lesion analysis, using a five-point scale for receiver operating characteristic (ROC) curve analysis. A panel of reference methodswas used, including MRI (28 patients), planar x-ray (17 patients), and spiral computed tomography (four patients). RESULTS: With F-18–PET, 64 bone metastases were detected in 17 patients. Only 29 metastases were detected in 11 patients with BS. As a result of F-18–PET imaging, clinical management was changed in four patients (11.7%). For F-18–PET, the area under the ROC curve was 0.99 on a lesion basis (for BS, it was 0.74; P < .05) and 1.00 on a patient basis (for BS, it was 0.82; P < .05). CONCLUSION: F-18–PET demonstrates a very early bone reaction when small bone marrow metastases are present, allowing accurate detection of breast cancer bone metastases. This accurate detection has a significant effect on clinical management, compared with the effect on management brought about by detection with conventional BS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bezwoda, W. R., Seymour, L., & Dansey, R. D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2483 · Cited by 400
RetractedHanley, J. A., & McNeil, B. J. (1983) · Radiology · doi:10.1148/radiology.148.3.6878708 · Cited by 7,016
The clinical course of bone metastases from breast cancer
Coleman, R., & Rubens, R. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.13 · Cited by 1,084
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I. J., Solomayer, E.-F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki, A., Boyce, B. F., Story, B. M., Wright, K. R., Chapman, M., Boyce, R. W., Mundy, G. R., & Yoneda, T. (1995) · PubMed · Cited by 417
Antman, K. H., Rowlings, P. A., Vaughan, W. P., Pelz, C. J., Fay, J. W., Fields, K. K., Freytes, C. O., Gale, R. P., Hillner, B. E., Holland, H. K., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1870 · Cited by 323
van Holten-Verzantvoort, A. T., Bijvoet, O. L. M., Hermans, J., Harinck, H. I. J., Elte, J. W. F., Beex, L. V. A. M., Cleton, F. J., Kroon, H. M., Vermey, P., Neijt, J. P., et al. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92555-4 · Cited by 202
Ayash, L. J., ELIAS, A. D., Wheeler, C., et al. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.37 · Cited by 143
Gibril, F., Doppman, J. L., Reynolds, J. C., Chen, C. C., Sutliff, V. E., Yu, F., Serrano, J., Venzon, D. J., & Jensen, R. T. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1040 · Cited by 142
RADIOIMMUNOIMAGING FOR DIAGNOSIS OF BONE MARROW INVOLVEMENT IN BREAST CANCER AND MALIGNANT LYMPHOMA
Reske, S. N., Gloeckner, W., Schwarz, A., Jh, K., Steinsträsser, A., Ammon, J., & Buell, U. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91309-3 · Cited by 76
Self-citation
Cited by
(2001) · PubMed · Cited by 943
Bone Imaging in Metastatic Breast Cancer
Hamaoka, T., Madewell, J. E., Podoloff, D. A., Hortobagyi, G. N., & Ueno, N. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.181 · Cited by 656
Skeletal PET with18F-Fluoride: Applying New Technology to an Old Tracer
Grant, F. D., Fahey, F. H., Packard, A. B., Davis, R. T., Alavi, A., & Treves, S. T. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037200 · Cited by 520
Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy
Yang, H.-L., Liu, T., Wang, X.-M., Xu, Y., & Deng, S.-M. (2011) · European Radiology · doi:10.1007/s00330-011-2221-4 · Cited by 374
Lecouvet, F. E., El Mouedden, J., Collette, L., Coche, E., Danse, E., Jamar, F., Machiels, J.-P., Vande Berg, B., Omoumi, P., & Tombal, B. (2012) · European Urology · doi:10.1016/j.eururo.2012.02.020 · Cited by 303
Metadata
- Authors
- Schirrmeister, H., Guhlmann, A., Kotzerke, J., Santjohanser, C., Kühn, T., Kreienberg, R., Messer, P., Nüssle, K., Elsner, K., Glatting, G., Träger, H., Neumaier, B., Diederichs, C., & Reske, S. N.
- Venue
- Journal of Clinical Oncology
- Published
- 1999-08
- Volume
- 17
- Issue
- 8
- Pages
- 2381-2381
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1910380884
- Cited by
- 283
- References
- 12
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early Detection and Accurate Description of Extent of Metastatic Bone Disease in Breast Cancer With Fluoride Ion and Positron Emission Tomography. https://app.cochat.ai/papers/10.1200/jco.1999.17.8.2381
- The paper
- Schirrmeister, H., Guhlmann, A., Kotzerke, J., Santjohanser, C., Kühn, T., Kreienberg, R., Messer, P., Nüssle, K., Elsner, K., Glatting, G., Träger, H., Neumaier, B., Diederichs, C., & Reske, S. N. (1999). Early Detection and Accurate Description of Extent of Metastatic Bone Disease in Breast Cancer With Fluoride Ion and Positron Emission Tomography. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1999.17.8.2381
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.